SCHEMBL4267409

SCHEMBL4267409

Oc1cc(O)cc(C#Cc2ccccc2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 2/20 0.60
AKR1C2 P52895 1/20 0.47
AKR1C1 Q04828 1/20 0.47
HNF4A P41235 1/20 0.47
MAPT P10636 2/20 0.46
FFAR1 O14842 4/20 0.43
CA12 O43570 2/20 0.43
CA1 P00915 2/20 0.43
CA2 P00918 2/20 0.43
CA9 Q16790 2/20 0.43
GRM5 P41594 1/20 0.43
FFAR4 Q5NUL3 1/20 0.42
NPC1 O15118 2/20 0.41
ABL1 P00519 1/20 0.41
ABCB1 P08183 1/20 0.41
BCR P11274 1/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP1A2 P05177 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19026498 0.98 APP (0.57) APPAKR1C2AKR1C1HNF4AMAPT
SCHEMBL20211704 0.95 APP (0.60) APPAKR1C2AKR1C1HNF4AMAPT
Acetic Acid SCHEMBL20211708 0.85 AKR1C2 (0.49) APPAKR1C2AKR1C1HNF4AMAPT
SCHEMBL18549484 0.84 APP (0.67) APPAKR1C2AKR1C1HNF4AMAPT
SCHEMBL673158 0.84 APP (0.61) APPMAPTCA12CA1CA2
SCHEMBL717647 0.84 APP (0.67) APPAKR1C2AKR1C1HNF4AMAPT
SCHEMBL674063 0.84 BACE1 (0.57) APPMAPTCA12CA1CA2
SCHEMBL722068 0.83 CA12 (0.59) APPAKR1C2AKR1C1HNF4AMAPT
SCHEMBL30493627 0.83 CA12 (0.59) APPAKR1C2AKR1C1HNF4AMAPT
Diphenylacetylene SCHEMBL28319096 0.81 APP (0.71) APPHNF4AMAPTFFAR1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009126700-A1 HYDROXYLATED TOLANS AND RELATED COMPOUNDS AS COSMETICS OR THERAPEUTICS FOR SKIN CONDITIONS KENT STATE UNIVERSITY (US) 2009-10-15 WO claimed
EP-3280402-B1 TOLAN COMPOUNDS FOR PROMOTING WOUND HEALING BIOMENDICS LLC (US) 2024-06-05 EP disclosed
US-11786481-B2 Formulation and process for modulating wound healing BioMendics, LLC (US) 2023-10-17 US disclosed
US-20220296538-A1 Substituted Tolans for the Modulation of Microbial Colonization BioMendics, LLC (US) 2022-09-22 US disclosed
US-11351126-B2 Substituted tolans for the modulation of microbial colonization BioMendics, LLC (US) 2022-06-07 US disclosed
US-20210228501-A1 Formulation and Process for Modulating Wound Healing BioMendics, LLC (US) 2021-07-29 US disclosed
US-20200206154-A1 Substituted Tolans for the Modulation of Microbial Colonization BioMendics, LLC (US) 2020-07-02 US disclosed
US-10426742-B2 Formulation and process for modulating wound healing BioMendics, LLC (US) 2019-10-01 US disclosed
US-20190022029-A1 Formulation and Process for Modulating Wound Healing BioMendics, LLC (US) 2019-01-24 US disclosed
US-20160296477-A1 Formulation and Process for Modulating Wound Healing BioMendics, LLC (US) 2016-10-13 US disclosed
WO-2009126700-A1 HYDROXYLATED TOLANS AND RELATED COMPOUNDS AS COSMETICS OR THERAPEUTICS FOR SKIN CONDITIONS KENT STATE UNIVERSITY (US) 2009-10-15 WO disclosed
US-4654412-A UNSATURATED MONOMERS, FIBERS, FILMS, MOLDINGS CELANESE CORPORATION (US) 1987-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11786481-B2 Formulation and process for modulating wound healing SQSTM1, ATG7, TFEB APP 4010/4885AKR1C2 2005/4885AKR1C1 1878/4885
US-20200206154-A1 Substituted Tolans for the Modulation of Microbial Colonization LMAN1, DPM1, DSTN APP 3466/4885AKR1C2 4188/4885AKR1C1 4040/4885
US-20160296477-A1 Formulation and Process for Modulating Wound Healing SQSTM1, ATG7, TFEB APP 4260/4885AKR1C2 1888/4885AKR1C1 1645/4885
US-20210228501-A1 Formulation and Process for Modulating Wound Healing ATG7, SQSTM1, ATF4 APP 3850/4885AKR1C2 2016/4885AKR1C1 1901/4885
US-10426742-B2 Formulation and process for modulating wound healing SQSTM1, ATG7, TFEB APP 4010/4885AKR1C2 2005/4885AKR1C1 1878/4885
US-20190022029-A1 Formulation and Process for Modulating Wound Healing SQSTM1, ATG7, TFEB APP 4010/4885AKR1C2 2005/4885AKR1C1 1878/4885
US-11351126-B2 Substituted tolans for the modulation of microbial colonization LMAN1, DPM1, DSTN APP 3466/4885AKR1C2 4188/4885AKR1C1 4040/4885
US-20220296538-A1 Substituted Tolans for the Modulation of Microbial Colonization LMAN1, DPM1, DSTN APP 3466/4885AKR1C2 4188/4885AKR1C1 4040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.